Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease

Authors Anand A Dalal, Melissa H Roberts, Hans V Petersen, et al

Published 31 December 2010 Volume 2011:6 Pages 13—22

DOI https://doi.org/10.2147/COPD.S15455

Review by Single-blind

Peer reviewer comments 2

Anand A Dalal1, Melissa H Roberts2, Hans V Petersen2, Christopher M Blanchette3, Douglas W Mapel4
1US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC; 2Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Albuquerque, NM; 3Kannapolis, North Carolina; 4Lovelace Clinic Foundation, Albuquerque, NM, USA

Purpose: Relative costs and utilization-related outcomes of a fluticasone propionate 250 µg + salmeterol 50 µg combination (FSC), tiotropium bromide, and ipratropium as initial maintenance therapy in COPD have not been compared in a commercially-insured population.
Methods: This retrospective, observational cohort study used health care claims data from January 2004 to June 2009 from a large administrative database for patients aged ≥40 years with COPD. Time-to-first COPD-related health care event beginning 30 days following therapy initiation with FSC (n = 16,684), ipratropium alone or in fixed dose combination with albuterol (n = 14,449), or tiotropium (n = 12,659) was estimated using Cox proportional hazard models that controlled for differences in patient demographic characteristics, health care utilization, and comorbidities at baseline. Mean adjusted costs and numbers of COPD-related health care encounters and prescription medication fills were compared among patients with 12 months of follow-up (FSC, n = 12,595; ipratropium, n = 10,617; tiotropium, n = 9126).
Results: With FSC as the reference, risk for a COPD-related hospitalization and/or emergency department visit was significantly higher for ipratropium (hazard ratio [HR] 1.64, 95% confidence interval [CI] 1.50–1.79) and tiotropium (HR 1.29, CI 1.17–1.41). Mean adjusted 12-month COPD-related total health care costs were lower for FSC ($2068, standard deviation [SD] $1190) than for ipratropium ($2841, SD $1858) and tiotropium ($2408, SD $1511, both P < 0.05). Mean number of COPD-related hospitalizations, emergency department visits, and outpatient visits associated with an oral corticosteroid or antibiotic were also lower for FSC than for ipratropium and tiotropium (all P < 0.05).
Conclusions: In this retrospective “real-world” observational sample of COPD patients, initiating treatment with FSC was associated with significantly better clinical and economic outcomes compared with short- and long-acting anticholinergic therapy. Consistent with the goal of preventing and reducing exacerbations advocated by global guidelines, the findings suggest that initiation of maintenance treatment with FSC may afford clinical benefits at a lower cost than anticholinergic treatment.

Keywords: chronic obstructive pulmonary disease, Advair®, tiotropium, ipratropium, utilization, costs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Treatment patterns of chronic obstructive pulmonary disease in employed adults in the United States

Diette GB, Dalal AA, D’Souza AO, Lunacsek OE, Nagar SP

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:415-422

Published Date: 24 February 2015

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:573-581

Published Date: 9 November 2011

Direct costs of chronic obstructive pulmonary disease among managed care patients

Anand A Dalal, Laura Christensen, Fang Liu, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:341-349

Published Date: 30 September 2010

Readers of this article also read:

Outcome of pulmonary rehabilitation in COPD patients with severely impaired health status

van Ranst D, Otten H, Meijer JW, van 't Hul AJ

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:647-657

Published Date: 1 December 2011

Factors associated with good self-rated health and quality of life in subjects with self-reported COPD

Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:511-519

Published Date: 7 October 2011

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD

Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:353-363

Published Date: 23 June 2011

Economic burden of chronic bronchitis in the United States: a retrospective case-control study

Christopher M Blanchette, Melissa H Roberts, Hans Petersen, et al 

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:73-81

Published Date: 13 January 2011